Interest in using oral ondansetron combined with methylprednisolone in moderately emetogenic chemotherapy;Interet de l'association ondansetron comprime et methylprednisolone des la premiere cure dans les chimiotherapies moyennement emetisantes

Bulletin du Cancer

Volumn 84, Issue 8, 1997, Pages 781-787

  Coiffier, Bertrand ^a   Khayat, David ^b   Misset, Jean Louis ^c   Votan, Bénédicte ^d   Abgrall, J F ^e   Arlet, E ^e   Bordessoule, D ^e   Bouffette, P ^e   Bourquard, P ^e   Breteau, N ^e   Capdeville, J ^e   Chantelard, J V ^e   Chollet, P ^e   Corette, L ^e   Crestin, M ^e   De Broucker, D ^e   De Gramont, A ^e   Delzenne, A ^e   Dreyfus, B ^e   Dumont, J ^e   Eghbali, H ^e   Eskandari, J ^e   Fabrics, J P ^e   Fargeot, P ^e   Fayolle, V ^e   Foa, J ^e   Frobert, J L ^e   Froger, X ^e   Gabarre, J ^e   Gastaut, J A ^e   Goudier, M J ^e   Guyon, J M ^e   Guyotat, D ^e   Haegele, P ^e   Jaubert, D ^e   Kohn, M ^e   Laplaige, P ^e   Leduc, B ^e   Lepeu, G ^e   Lepille, D ^e   Le Porrier, M ^e   Malhaire, J P ^e   Mandet, J ^e   Mittal, P ^e   Peny, A M ^e   Pouillart, P ^e   Prevot G ^e   Pujade Lauraine, E ^e   Renou, P ^e   Renoux, M ^e   Rossi, J F ^e   Simon, M ^e   Slawinski, J C ^e   Sotto, J J ^e   Travade, P ^e   Vincent, M ^e   Van Vu, H ^e   Zylberberg, B ^e   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d Glaxo Laboratories   (France)

^e NONE

Author keywords

Emesis; Moderately emetogenic chemotherapy; Oral ondansetron; Standard anti emetic regimen

Indexed keywords

ALKYLATING AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXCHLORPHENIRAMINE MALEATE; DOXORUBICIN; FLUOROURACIL; HYDROXYZINE; METHYLPREDNISOLONE; METOPIMAZINE; ONDANSETRON; PHLOROGLUCINOL; PREDNISONE; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VOMITING; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG TOLERANCE; MIDDLE AGED; QUALITY OF LIFE; REVIEW; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; LYMPHOMA; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; ONDANSETRON; QUALITY OF LIFE; SINGLE-BLIND METHOD; VOMITING;

EID: 0031202226     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Grollo R. Approaches to management of nausea and vomiting in the clinical setting. Clinician 1988 ; 6 : 26-38.
2. Morrow GR, Loughner JE, Bennett JM. Prevalence of nausea and vomiting and other side-effects in patients receiving cytoxan, methotrexate, fluorouracile (CMF) therapy with and without prednisone. Proceedings of ASCO 1984 : 3, abst. 408.
3. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB, Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988 ; 94 : 397-412.
4. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991 ; 338 : 483-7.
5. Kaasa S, Kvaloy S, Dicato MA, Ries F, Huys JV, Royer E. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting : a randomized, double-blind study, Eur J Cancer 1990 ; 26 : 311-4.
6. Marschner N, Adler M, Nagel GA, Christmann D, Double-blind randomised trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide, Eur J Cancer 1991 ; 27 (suppl. 1) : 526.
7. Bonneterre J, Chevallier B, Metz R, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990 ; 8 : 1063-9.
8. Beck MT, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993 ; 118 : 407-13.
9. Buser KS, Joss RA, Piquet D, et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracile (CMF) in women breast cancer. Results of a prospective, randomized double-blind, placebo-controlled study. Ann Oncol 1993 ; 4 : 475-9.
10. Bonneterre J, Clavel M and the Ondansetron Breast Cancer Study Group. Comparison between ondansetron table and alizapride injection in the prevention of emesis induced by cytotoxic regimens in breast cancer patients. Ann Oncol 1992 ; 3 (suppl. 5) : 699.
11. Clavel M, Bonneterre J, d'Allens H, Paillarse JM et le Groupe français d'étude de l'ondansétron, Utilisation exclusive du comprimé d'ondansétron dans la prévention des troubles émétiques induits par les chimiothérapies des cancers du sein. Cah Oncol 1993 ; 2 : 189-94.
12. Chevallier B, Marty M, Paillarse JM and the Ondansetron Study Group. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed dsplatin-induced emesis over at least three cycles. Br J Cancer 1994 ; 70 : 1171-5.
13. Hesketh PJ, Harvey WG, Beck T, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994 ; 12 : 596-600.
14. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis : a double-blind multicenter randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991 ; 9 : 675-8.
15. Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991 ; 338 : 487-90.
16. Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron ? Br Med J 1991 ; 303 : 1423-6.
17. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992 ; 49 : 295-304.
18. Hirsch JD, Lee JT, Grapski R. Quality of life with intravenous ondansetron vs standard antiemetic therapy in patients receiving emetogenic cancer chemotherapy. Proceedings of ASCO 1992 ; 11 : 393, abst. 1368.
19. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients : the functional living index-cancer : development and validation. J Clin Oncol 1984 ; 2 : 472-83.
20. Dicato MA, Freeman AJ. Experience with ondansetron in chemotherapy and radiotherapy-induced emesis. Eur J Anaesthesiol 1992 ; 9 (suppl. 6) : 19-24.
21. Richard A, Chevallier B, Marry M. Construction et validation d'un modèle prédictif du contrôle de l'émésis au fil des cures de chimiothérapie. Cah Oncol 1994 ; 3 : 279-83.
22. Franchi M, Donadello N, Zanaboni F, et al. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. Oncology 1995 ; 52 : 509-12.
23. Gagen M, Gochnour D, Young D, Gaginella T, Neidhart J. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy induced vomiting. J Clin Oncol 1984 ; 2 : 696-701.
24. Gralla RJ. Metoclopramide : a review of antiemetic trials. Drugs 1983; 25 (suppl. 1) : 63-73.
25. Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995 ; 3 : 11-22.
26. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992 ; 19 (6, suppl. 15): 26-32.
27. Richard A, Marty M, Étude des facteurs pronostiques des vomissements induits par les chimiothérapies anticanéreuses chez 2 041 patients. Cah Oncol 1993 ; 2 : 175-80.